Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : UCB6114,Trifluridine,Tipiracil HCl
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration focuses on the development of two antibody candidates, UCB6114 and UCB4594 by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB’s renowned antibody disco...
Product Name : UCB6114
Product Type : Antibody
Upfront Cash : Undisclosed
September 03, 2023
Lead Product(s) : UCB6114,Trifluridine,Tipiracil HCl
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration
Details : The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 03, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TGL-100
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Touchlight
Deal Size : Undisclosed
Deal Type : Partnership
Details : The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Product Name : TGL-100
Product Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : TGL-100
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Touchlight
Deal Size : Undisclosed
Deal Type : Partnership